<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-1249</journal-id>
<journal-title><![CDATA[Archivos de Pediatría del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Pediatr. Urug.]]></abbrev-journal-title>
<issn>1688-1249</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Pediatría]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-12492025000301205</article-id>
<article-id pub-id-type="doi">10.31134/ap.96.17</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Características clínicas, terapéuticas y evolutivas de enfermedad asociada a anti-MOG en pacientes pediátricos]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical, therapeutic and evolutionary characteristics of anti-MOG-associated disease in pediatric patients]]></article-title>
<article-title xml:lang="pt"><![CDATA[Características clínicas, terapêuticas e evolutivas da doença associada a anti-MOG em pacientes pediátricos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morón]]></surname>
<given-names><![CDATA[Aroldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pedemonte]]></surname>
<given-names><![CDATA[Virginia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cerisola]]></surname>
<given-names><![CDATA[Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Neuropediatría]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Neuropediatría]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Neuropediatría]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Neuropediatría]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>96</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-12492025000301205&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-12492025000301205&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-12492025000301205&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  las enfermedades inflamatorias desmielinizantes constituyen un amplio espectro de enfermedades con compromiso del sistema nervioso central. Dentro de ellas se ubica la enfermedad asociada a anticuerpos contra la glucoproteína de la mielina de los oligodendrocitos (MOGAD). Esta incluye síndromes con compromiso de sustancia blanca y gris. MOGAD se diagnostica mediante anticuerpos anti-MOG, el tratamiento de elección es la inmunoterapia, presentando un buen pronóstico en la mayoría de los casos, aunque algunas formas recidivantes requieren tratamiento de mantenimiento.  Objetivos:  describir las características clínicas, los tratamientos realizados y la evolución de un grupo de niños con diagnóstico de MOGAD atendidos en el Servicio de Neuropediatría del Centro Hospitalario Pereira Rossell entre enero de 2022 y junio de 2024.  Metodología:  estudio observacional, descriptivo, retrospectivo, basado en historias clínicas de 14 pacientes con MOGAD.  Resultados:  se incluyeron 14 pacientes (6 niñas y 8 niños) de 2 a 14 años, con una media de 8,7 años al momento del diagnóstico. Los fenotipos clínicos fueron: encefalomielitis diseminada aguda (n=1), mielitis transversa extensiva (n=4), espectro de neuromielitis óptica (n=4), encefalitis (n=4) y síndrome neurológico monofocal (n=1). Todos los pacientes recibieron metilprednisolona endovenosa, siendo este el único tratamiento en diez casos. Dos pacientes, además, requirieron plasmaféresis, uno inmunoglobulina intravenosa (IGIV), y otro, plasmaféresis, IGIV y rituximab. Cuatro pacientes presentaron recaídas, tres con neuritis óptica. Dos fueron tratados con azatioprina y dos con rituximab. Un paciente permanece con inmunosupresión debido a la gravedad inicial.  Conclusiones:  MOGAD es una enfermedad desmielinizante con variados fenotipos clínicos. Requiere un alto índice de sospecha, existiendo un biomarcador específico y sensible. Habitualmente la respuesta al tratamiento es buena, con pocas recaídas y baja tasa de secuelas neurológicas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  inflammatory Demyelinating Diseases include a broad spectrum of diseases involving the central nervous system. Among them, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) includes syndromes affecting both white and gray matter. MOGAD is identified through anti-MOG antibodies and is treated with immunotherapy, generally presenting a good prognosis in most cases, although some relapsing forms require prolonged treatment.  Objectives:  describe the clinical characteristics, treatments administered, and outcomes of a group of children diagnosed with MOGAD, treated at the Pediatric Neurology Service of the Centro Hospitalario Pereira Rossell between January 2022 and June 2024.  Methodology:  observational, descriptive, retrospective study based on the clinical records of 14 patients with MOGAD.  Results:  we included 14 patients (6 girls and 8 boys) aged 2 to 14 years, with a mean age of 8.7 years. The clinical phenotypes were: acute disseminated encephalomyelitis (n=1), extensive transverse myelitis (n=4), neuromyelitis optica spectrum (n=4), encephalitis (n=4), and monofocal neurological syndrome (n=1). All received intravenous methylprednisolone, which was the only treatment in 9 cases. Two patients additionally required plasmapheresis, one intravenous immunoglobulin (IVIG), and another plasmapheresis, IVIG, and rituximab. Four patients relapsed, three with optic neuritis. Two were treated with azathioprine and two with rituximab. One patient remains under immunosuppression due to the initial severity.  Conclusions: MOGAD is a demyelinating disease with varied clinical phenotypes. It requires a high level of suspicion, with a specific and sensitive biomarker available. The response to treatment is generally good, with few relapses and a low rate of neurological sequelae.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  as doenças inflamatórias desmielinizantes constituem um amplo espectro de doenças com comprometimento do sistema nervoso central. Dentro delas, encontra-se a doença associada a anticorpos contra a glicoproteína da mielina dos oligodendrócitos (MOGAD). Esta inclui síndromes com comprometimento de substância branca e cinzenta. A MOGAD é diagnosticada mediante anticorpos anti-MOG; o tratamento de eleição é a imunoterapia, apresentando um bom prognóstico na maioria dos casos, embora algumas formas recidivantes requeiram tratamento de manutenção.  Objetivos:  descrever as características clínicas, os tratamentos realizados e a evolução de um grupo de crianças com diagnóstico de MOGAD atendidas no Serviço de Neuropediatria do Centro Hospitalar Pereira Rossell entre janeiro de 2022 e junho de 2024.  Metodologia:  estudo observacional, descritivo, retrospectivo, baseado em prontuários clínicos de 14 pacientes com MOGAD.  Resultados:  foram incluídos 14 pacientes (6 meninas e 8 meninos) de 2 a 14 anos, com uma média de 8,7 anos no momento do diagnóstico. Os fenótipos clínicos foram: encefalomielite disseminada aguda (n=1), mielite transversa extensiva (n=4), espectro de neuromielite óptica (n=4), encefalite (n=4) e síndrome neurológica monofocal (n=1). Todos os pacientes receberam metilprednisolona endovenosa, sendo este o único tratamento em 10 casos. Dois pacientes adicionalmente necessitaram de plasmaférese, um imunoglobulina intravenosa (IGIV), e outro plasmaférese, IGIV e rituximabe. Quatro pacientes apresentaram recaídas, três com neurite óptica. Dois foram tratados com azatioprina e dois com rituximabe. Um paciente permanece com imunossupressão devido à gravidade inicial.  Conclusões:  a MOGAD é uma doença desmielinizante com variados fenótipos clínicos. Requer um alto índice de suspeita, existindo um biomarcador específico e sensível. Habitualmente a resposta ao tratamento é positiva, com poucas recaídas e baixa taxa de sequelas neurológicas.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad Asociada a Anticuerpos contra la Glucoproteína de Oligodendrocito de Mielina]]></kwd>
<kwd lng="es"><![CDATA[Niño]]></kwd>
<kwd lng="en"><![CDATA[Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease]]></kwd>
<kwd lng="en"><![CDATA[Child]]></kwd>
<kwd lng="pt"><![CDATA[Doença Associada a Anticorpos contra a Glicoproteína de Oligodendrócitos da Mielina]]></kwd>
<kwd lng="pt"><![CDATA[Criança]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruijstens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lechner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Flet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Deiva]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Neuteboom]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hemingway]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[E U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders]]></article-title>
<source><![CDATA[Eur J Paediatr Neurol]]></source>
<year>2020</year>
<volume>29</volume>
<page-range>2-13</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banwell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sadovnick]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Magalhaes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wambera]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of acquired demyelination of the CNS in Canadian children]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2009</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>232-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krupp]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tardieu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Amato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Banwell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chitnis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dale]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders revisions to the 2007 definitions]]></article-title>
<source><![CDATA[Mult Scler]]></source>
<year>2013</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1261-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ketelslegers]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Catsman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Neuteboom]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Boon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van Dijk]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelenboom]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of acquired demyelinating syndromes of the CNS in Dutch children a nationwide study]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2012</year>
<volume>259</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1929-35</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reindl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Pauli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rostásy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The spectrum of MOG autoantibody-associated demyelinating diseases]]></article-title>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2013</year>
<volume>9</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>455-61</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lassmann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Waehneldt]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matthieu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Linington]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats]]></article-title>
<source><![CDATA[J Neurochem]]></source>
<year>1989</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>296-304</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hemmer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Archelos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New concepts in the immunopathogenesis of multiple sclerosis]]></article-title>
<source><![CDATA[Nat Rev Neurosci]]></source>
<year>2002</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>291-301</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jurynczyk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Messina]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Woodhall]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Raza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Everett]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Roca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical presentation and prognosis in MOG-antibody disease a UK study]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2017</year>
<volume>140</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3128-38</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramanathan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tantsis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Merheb]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fung]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2018</year>
<volume>89</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>127-37</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hennes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Baumann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lechner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rostásy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MOG spectrum disorders and role of MOG-antibodies in clinical practice]]></article-title>
<source><![CDATA[Neuropediatrics]]></source>
<year>2018</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-11</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hacohen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Absoud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Deiva]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hemingway]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nytrova]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Woodhall]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children]]></article-title>
<source><![CDATA[Neurol Neuroimmunol Neuroinflamm]]></source>
<year>2015</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics and prognosis of pediatric myelin oligodendrocyte glycoprotein antibody-associated diseases in China]]></article-title>
<source><![CDATA[BMC Pediatr]]></source>
<year>2022</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>666</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivé]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Armangué]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primer episodio desmielinizante y enfermedad asociada a anticuerpos contra MOG]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Caraballo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Campistol]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuropediatría: fundamentos prácticos]]></source>
<year>2023</year>
<page-range>1075-87</page-range><publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armangue]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Capobianco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de Chalus]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Laetitia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Deiva]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[E U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders]]></article-title>
<source><![CDATA[Eur J Paediatr Neurol]]></source>
<year>2020</year>
<volume>29</volume>
<page-range>22-31</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marchionatti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hansel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Avila]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of MOG-IgG in clinical samples by live cell-based assays performance of immunofluorescence microscopy and flow cytometry]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2021</year>
<volume>12</volume>
<page-range>642272</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baumann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bartels]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Finke]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Adamsbaum]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hacohen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Rostásy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[E U. paediatric MOG consortium consensus: Part 2 - Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders]]></article-title>
<source><![CDATA[Eur J Paediatr Neurol]]></source>
<year>2020</year>
<volume>29</volume>
<page-range>14-21</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruijstens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wendel]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lechner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bartels]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Finke]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Breu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[E U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders]]></article-title>
<source><![CDATA[Eur J Paediatr Neurol]]></source>
<year>2020</year>
<volume>29</volume>
<page-range>41-53</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jarius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ruprecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kleiter]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Borisow]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Asgari]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pitarokoili]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MOG-IgG in NMO and related disorders a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome]]></article-title>
<source><![CDATA[J Neuroinflammation]]></source>
<year>2016</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>280</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armangue]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Olivé]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sepulveda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies a multicentre observational study]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2020</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>234-46</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruijstens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Breu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wendel]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wassmer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Neuteboom]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[E U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders]]></article-title>
<source><![CDATA[Eur J Paediatr Neurol]]></source>
<year>2020</year>
<volume>29</volume>
<page-range>32-40</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banwell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marignier]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brilot]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Flanagan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease International MOGAD Panel proposed criteria]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2023</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>268-82</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
